# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-25-125282
**Filing Date:** 2025-12
**Character Count:** 8047
**Document Hash:** bec2ad7a3815e9301ae24a4885d8673c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-125282.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001213900-25-125282

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20251222

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38793
- **FILM NUMBER:** 251600401

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): December 22, 2025

---

| |
|:---|
| **INMUNE BIO INC.** |
| (Exact name of registrant as specified in charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-38793** | **47-5205835** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification No.) |

---

**<u>225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432</u>**

(Address of Principal Executive Offices) (Zip Code)

**<u>(561) 710-0512</u>**

(Registrant's Telephone Number, Including Area Code)

**<u>Not Applicable</u>**

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per shares INMB | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

On December 22, 2025, INmune Bio Inc. (the "Company") entered into an amendment (the "Warrant Amendment") with certain holders of warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, respectively (the "April 2024 Warrants"). The exercise price of an aggregate of 1,348,315 outstanding April 2024 Warrants was (i) reduced to $1.95, which price is greater than Minimum Price (as defined in Nasdaq Listing Rule 5635(d)) as of December 17, 2025, and (ii) the term of such April 2024 Warrants was extended such that they will expire on June 30, 2026. As consideration for the Warrant Amendment, the holders paid the Company $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416.

The foregoing summary of the Warrant Amendment does not purport to be complete and is qualified in its entirety by reference to the form of the Warrant Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1 | [Form of Warrant Amendment](ea027072301ex10-1_inmune.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INMUNE BIO INC.** | **INMUNE BIO INC.** |
| Date: December 23, 2025 | By: | */s/ David Moss* |
|  |  | David Moss |
|  |  | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**FORM OF AMENDMENT TO WARRANT** 

This Amendment to Common Stock Purchase Warrant (this "**Amendment**") is entered into and shall become effective as of the date on which **INmune Bio Inc.** a Nevada corporation (the "**Company**") receives both (i) payment of the Amendment Consideration (as defined below) and (ii) a duly executed copy of this Amendment from the undersigned holder ("**Holder**") (such date, the "**Effective Date**").

WHEREAS, the Holder is the holder of that certain warrant issued by the Company to the Holder on ___________, 2024 (the "**Warrant**");

WHEREAS, the Company and the Holder desire to amend the Warrant as more particularly set forth below in exchange for the Amendment Consideration; WHEREFORE, the parties do hereby agree as follows:

1. The portion of the Warrant's first paragraph:

"*and on or prior to 5:00pm (New York City time) on the earlier of (1) the two (2) year anniversary of the Initial Exercise Date or (2) thirty (30) Trading Days following the reporting of positive top line data (EMACC p-value of less than or equal to 0.05) in the Phase 2 Alzheimer's program of XPro1595,*"

is hereby amended and replaced with the following:

"*and on or prior to 5:00pm (New York City time) on June 30, 2026*"

2. The first sentence of Section 2(b) of the Warrant is hereby amended and replaced in its entirety to read:

"*The exercise price of this Warrant shall be $1.95 per share, subject to adjustment hereunder (the "<u>Exercise Price</u>").*"

3. As consideration for this Amendment, the Holder shall pay to the Company $0.05 for each Warrant held by the Holder as of the Effective
Date (the "**Amendment Consideration** "). The effectiveness of this Amendment is expressly conditioned upon the Company's
receipt of the full Amendment Consideration.

4. The Holder must execute and return this Amendment to the Company, together with the Amendment Consideration, no later than **December 22, 2025** (the "**Execution Deadline** "). If the Holder does not execute and return this Amendment, together with the
Amendment Consideration, to the Company by the Execution Deadline, this Amendment shall be null and void and of no force or effect.

5. Except as expressly amended herein, all terms and conditions of the Warrant shall remain in full force and effect.

6. This Amendment shall be governed by and construed in accordance with the laws governing the Warrant.

7. This Amendment may be executed in counterparts, each of which shall be deemed an original, and shall be binding upon all parties,
their successors and assigns, and all of which taken together shall constitute one and the same Amendment. A signature delivered by facsimile
or email shall constitute an original.

[Signature Page Follows]

**INmune Bio Inc.** 

By:  <br> Name: <br> Title:

**HOLDER**

By:  <br> Name: <br> Title: